Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF) has announced the creation of a wholly owned U.S. subsidiary, Alera Pharma, Inc. This new entity will focus on neurology and be assigned the intellectual property rights for Lobe's lead compound, Psilocin Mucate. Key appointments include:
- Rick Goulburn as CEO of Alera Pharma
- Dr. Frederick D. Sancilio as Chairman of Alera Pharma's Board
- Dr. Harry Jacobson, Wesley Ramjeet, and Rick Goulburn as Board Members
- Ilan Hayman joining Alera's executive management team
Lobe Sciences Australia Pty will become a subsidiary of Alera Pharma. The company also received a Notice of Allowance from the US PTO for its Patent Application Serial No. 18/411,576. This restructuring aims to simplify Lobe Sciences' operations into three entities: Lobe Sciences , Alera Pharma, and Altemia,
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF) ha annunciato la creazione di una sussidiaria interamente controllata negli Stati Uniti, Alera Pharma, Inc. Questa nuova entità si concentrerà sulla neurologia e le verranno assegnati i diritti di proprietà intellettuale per il composto principale di Lobe, Psilocin Mucate. Le nomine chiave includono:
- Rick Goulburn come CEO di Alera Pharma
- Dr. Frederick D. Sancilio come Presidente del Consiglio di Alera Pharma
- Dr. Harry Jacobson, Wesley Ramjeet e Rick Goulburn come membri del Consiglio
- Ilan Hayman entrerà a far parte del team di gestione esecutiva di Alera
Lobe Sciences Australia Pty diventerà una sussidiaria di Alera Pharma. L'azienda ha anche ricevuto un Avviso di Ammissione dall'US PTO per la sua Domanda di Brevetto n. 18/411,576. Questa ristrutturazione mira a semplificare le operazioni di Lobe Sciences in tre entità: Lobe Sciences, Alera Pharma e Altemia.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF) ha anunciado la creación de una filial de propiedad total en EE. UU., Alera Pharma, Inc. Esta nueva entidad se centrará en neurología y se le asignarán los derechos de propiedad intelectual para el compuesto principal de Lobe, Psilocin Mucate. Los nombramientos clave incluyen:
- Rick Goulburn como CEO de Alera Pharma
- Dr. Frederick D. Sancilio como Presidente de la Junta de Alera Pharma
- Dr. Harry Jacobson, Wesley Ramjeet y Rick Goulburn como miembros de la Junta
- Ilan Hayman se unirá al equipo de gestión ejecutiva de Alera
Lobe Sciences Australia Pty se convertirá en una filial de Alera Pharma. La empresa también recibió un Aviso de Permiso de la USPTO para su Solicitud de Patente Serial No. 18/411,576. Esta reestructuración tiene como objetivo simplificar las operaciones de Lobe Sciences en tres entidades: Lobe Sciences, Alera Pharma y Altemia.
로브 사이언스(Lobe Sciences) (CSE: LOBE, OTCQB: LOBEF)는 완전 자회사인 Alera Pharma, Inc.의 설립을 발표했습니다. 이 새로운 법인은 신경학에 집중하며 로브의 주요 화합물인 Psilocin Mucate에 대한 지적재산권을 부여받게 됩니다. 주요 임명 사항은 다음과 같습니다:
- Rick Goulburn이 Alera Pharma의 CEO로 임명됨
- Dr. Frederick D. Sancilio가 Alera Pharma 이사회의 의장으로 임명됨
- Dr. Harry Jacobson, Wesley Ramjeet 및 Rick Goulburn이 이사로 임명됨
- Ilan Hayman이 Alera의 경영진 팀에 합류함
Lobe Sciences Australia Pty는 Alera Pharma의 자회사가 될 것입니다. 이 회사는 또한 미국 특허청(USPTO)로부터 특허 출원 번호 18/411,576에 대한 허가 통지를 받았습니다. 이번 구조조정은 Lobe Sciences의 운영을 Lobe Sciences, Alera Pharma, Altemia의 세 개의 엔티티로 단순화하는 것을 목표로 하고 있습니다.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF) a annoncé la création d'une filiale entièrement détenue aux États-Unis, Alera Pharma, Inc. Cette nouvelle entité sera axée sur la neurologie et se verra attribuer les droits de propriété intellectuelle concernant le composé phare de Lobe, Psilocin Mucate. Les nominations clés comprennent :
- Rick Goulburn en tant que PDG d'Alera Pharma
- Dr. Frederick D. Sancilio en tant que Président du Conseil d'Alera Pharma
- Dr. Harry Jacobson, Wesley Ramjeet et Rick Goulburn en tant que Membres du Conseil
- Ilan Hayman rejoignant l'équipe de direction exécutive d'Alera
Lobe Sciences Australia Pty deviendra une filiale d'Alera Pharma. L'entreprise a également reçu un Avis d'Admission de l'US PTO pour sa Demande de Brevet n° 18/411,576. Cette restructuration vise à simplifier les opérations de Lobe Sciences en trois entités : Lobe Sciences, Alera Pharma et Altemia.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF) hat die Gründung einer hundertprozentigen Tochtergesellschaft in den USA, Alera Pharma, Inc., bekannt gegeben. Diese neue Einheit wird sich auf Neurologie konzentrieren und erhält die geistigen Eigentumsrechte für Lobe's Hauptverbindung, Psilocin Mucate. Zu den wichtigen Ernennungen gehören:
- Rick Goulburn als CEO von Alera Pharma
- Dr. Frederick D. Sancilio als Vorsitzender des Vorstandes von Alera Pharma
- Dr. Harry Jacobson, Wesley Ramjeet und Rick Goulburn als Vorstandsmitglieder
- Ilan Hayman wird Teil des Führungsteams von Alera
Lobe Sciences Australia Pty wird eine Tochtergesellschaft von Alera Pharma. Das Unternehmen erhielt auch eine Erlaubnisbekanntgabe vom US-Patentamt für seine Patentanmeldung mit der Seriennummer 18/411,576. Diese Umstrukturierung zielt darauf ab, die Operationen von Lobe Sciences in drei Einheiten zu vereinfachen: Lobe Sciences, Alera Pharma und Altemia.
- Creation of Alera Pharma, Inc. as a wholly owned U.S. subsidiary focused on neurology
- Assignment of intellectual property rights for Psilocin Mucate to Alera Pharma
- Receipt of Notice of Allowance for U.S. Patent Application Serial No. 18/411,576
- Simplification of corporate structure into three entities: Lobe Sciences, Alera Pharma, and Altemia
- None.
- Alera Pharma, Inc. is a newly formed C-Corp wholly owned by Lobe Sciences, Ltd.
- Mr. Rick Goulburn is appointed as the Chief Executive Officer of Alera Pharma, Inc.
- Dr. Frederick D. Sancilio has been appointed as Chairman of the Alera Pharma, Inc. while Dr. Harry Jacobson, Mr. Wesley Ramjeet, and Mr. Goulburn are appointed as Members of the Board.
- Lobe Sciences Australia Pty Ltd. will become a subsidiary of Alera Pharma, Inc. and Mr. Ilan Hayman will become a member of the executive management team of Alera Pharma.
- Intellectual property rights associated with Lobe’s lead compound, Psilocin Mucate, will move to Alera Pharma.
- Notice of Allowance received from US PTO for US Patent Application Serial No. 18/411,576.
Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera.
Dr. Sancilio, Chairman and CEO of Lobe Sciences said, “At present, Lobe Sciences has a complex corporate structure. By establishing Alera Pharma, we are simplifying the operations of the Company into just three entities. Lobe Sciences, Ltd will provide common services to the two operating subsidiaries - Alera and Altemia, LLC. The creation of two separate operating companies will allow each entity to create value within their respective therapeutic areas; neurology and hematology.”
The Company also announces the receipt from the US PTO of a Notice of Allowance for its
About Lobe Sciences Ltd.
Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia®, a medical food designed to meet the needs of sickle cell patients globally.
Cautionary Statement Regarding "Forward-Looking" Information
This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the composition of the management team of Alera and the ownership of Lobe Sciences Australia Pty Ltd., are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the management team of Alera will be appointed as currently expected and that Lobe Sciences Australia Pty Ltd. will become a subsidiary of Alera as currently anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the management team of Alera will be appointed differently as currently expected and that Lobe Sciences Australia Pty Ltd. will not become a subsidiary of Alera as currently anticipated.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815293620/en/
For further information:
Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd.
Investor and Media
Info@Lobesciences.com
Phone: +1 (949) 505-5623
www.lobesciences.com
Source: Lobe Sciences Ltd
FAQ
What is the name of Lobe Sciences' new wholly owned subsidiary?
Who has been appointed as the CEO of Alera Pharma, Inc.?
What intellectual property rights will be assigned to Alera Pharma?
What is the stock symbol for Lobe Sciences ?
What patent-related news did Lobe Sciences announce?
